TY - JOUR
T1 - Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology
T2 - The Eastern Cooperative Oncology Group experience
AU - Paietta, E.
AU - Racevskis, J.
AU - Bennett, J. M.
AU - Neuberg, D.
AU - Cassileth, P. A.
AU - Rowe, J. M.
AU - Wiernik, P. H.
N1 - Funding Information:
This publication was supported by NCI, DHHS grants CA21115 (ECOG Operations Office), CA14958 (Einstein Cancer Center), CA23318 (Dana Farber Cancer Institute), CA11083 (University of Rochester), P30CA13330 (Einstein Cancer Center), the Phi Beta Psi Sorority and the Chemotherapy Foundation. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
PY - 1998
Y1 - 1998
N2 - Evaluable karyotypes were available in 776 of 1148 adult patients who were entered on acute myeloid leukemia (AML) treatment protocols of the Eastern Cooperative Oncology Group. Among these, we found seven patients (0.9%) with t(9;22)(q34;q11), the Philadelphia (Ph) chromosome, in bone marrow metaphases. All fulfilled the FAB criteria for AML (three M0, two M1, two M2), although one patient presented with an additional, distinct lymphoid blast cell population. Chromosomal aberrations in addition to the Ph chromosome were seen in four patients (including two cases of monosomy 7). Molecular analysis by polymerase chain reaction in four patients tested revealed variable BCR/ABL transcript forms (ela2, b2a2, b3a2, b2a3+e1a2). By immunophenotyping, all seven patients were myeloid based on the overall antigen expression pattern. However, all but one demonstrated lymphoid associated antigens on the myeloid blast cells. The six evaluable patients failed to respond to treatment with a standard anthracycline/cytosine arabinoside-containing regimen. We conclude that the incidence of the Ph chromosome in AML is very low. Although both genotypically and phenotypically heterogenous, Ph chromosome-positive AML, represents a clinically distinct entity with poor outcome.
AB - Evaluable karyotypes were available in 776 of 1148 adult patients who were entered on acute myeloid leukemia (AML) treatment protocols of the Eastern Cooperative Oncology Group. Among these, we found seven patients (0.9%) with t(9;22)(q34;q11), the Philadelphia (Ph) chromosome, in bone marrow metaphases. All fulfilled the FAB criteria for AML (three M0, two M1, two M2), although one patient presented with an additional, distinct lymphoid blast cell population. Chromosomal aberrations in addition to the Ph chromosome were seen in four patients (including two cases of monosomy 7). Molecular analysis by polymerase chain reaction in four patients tested revealed variable BCR/ABL transcript forms (ela2, b2a2, b3a2, b2a3+e1a2). By immunophenotyping, all seven patients were myeloid based on the overall antigen expression pattern. However, all but one demonstrated lymphoid associated antigens on the myeloid blast cells. The six evaluable patients failed to respond to treatment with a standard anthracycline/cytosine arabinoside-containing regimen. We conclude that the incidence of the Ph chromosome in AML is very low. Although both genotypically and phenotypically heterogenous, Ph chromosome-positive AML, represents a clinically distinct entity with poor outcome.
KW - Acute leukemia
KW - FAB
KW - Immunophenotype
KW - Myeloid
KW - Philadelphia chromosome
UR - http://www.scopus.com/inward/record.url?scp=0031730466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031730466&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2401229
DO - 10.1038/sj.leu.2401229
M3 - Article
C2 - 9844918
AN - SCOPUS:0031730466
SN - 0887-6924
VL - 12
SP - 1881
EP - 1885
JO - Leukemia
JF - Leukemia
IS - 12
ER -